Estrogen, HDL, and Coronary Heart Disease in Women

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Cardiovascular Diseases, Coronary Disease, Heart Diseases, Coronary Arteriosclerosis

In brief

To clarify the effects of estrogen, with or without progestin, on high density lipoprotein (HDL) in postmenopausal women.

Key facts

Study ID

NCT00083824

Run by

Tufts University

People needed

309

Starts

2004-03-01

Expected to finish

2007-02-01

Last updated by the study team

2016-04-21

Who can join

Age: 55 and older, up to 80. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• age >55 years without natural menses for at least 5 years or a serum FSH levels >40 IU/L without natural menses for at least 1 y or bilateral oophorectomy documented coronary artery disease

You may not qualify if…

• history of breast or endometrial carcinoma history of deep-vein thrombosis or pulmonary embolism previous or planned coronary bypass gallstones fasting TG levels >400 mg/dl uncontrolled diabetes uncontrolled hypertension serum creatinine >2 mg/dl a >70% stenosis of the left main coronary artery.

Where it is running

• HNRCA at Tufts University — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.